COVID-19 Related Coagulopathy: A Distinct Entity?
- PMID: 32486469
- PMCID: PMC7356260
- DOI: 10.3390/jcm9061651
COVID-19 Related Coagulopathy: A Distinct Entity?
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has impacted healthcare communities across the globe on an unprecedented scale. Patients have had diverse clinical outcomes, but those developing COVID-19-related coagulopathy have shown a disproportionately worse outcome. This narrative review summarizes current evidence regarding the epidemiology, clinical features, known and presumed pathophysiology-based models, and treatment guidance regarding COVID-19 coagulopathy.
Keywords: COVID-19; antiphospholipid antibodies; coronavirus disease 2019; endothelium; hemostasis; microparticles; thrombosis.
Conflict of interest statement
All the authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere in whole or part in any language. The authors disclose any financial associations that might pose a conflict of interest in connection with the submitted article.
Figures
References
-
- Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet. 2020;395:514–523. doi: 10.1016/S0140-6736(20)30154-9. - DOI - PMC - PubMed
-
- COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [(accessed on 28 April 2020)]; Available online: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd4029942....
Publication types
LinkOut - more resources
Full Text Sources
Medical
